Helicobacter pylori bacterial ghost containing recombinant Omp18 as a putative vaccine

Talebkhan, Yeganeh; Bababeik, M.; Esmaeili, Maryam; Oghalaei, A; Saberi, Samaneh; Karimi, Zeynab; Afkhami, N; Mohammadi, Marjan

doi:10.1016/j.mimet.2010.07.001

Cited by 26 publications

(17 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The lysis E gene encodes a hydrophobic protein which produces transmembrane channels and releases the cytoplasmic content of the pathogen. This leaves the empty bacterial cell envelop which retains the immunogenicity and is able to stimulate APCs for major histocompatibility presentation (Haslberger et al, 2000; Talebkhan et al, 2010). This technique has been exploited in a variety of Gram-negative bacterial vaccine development (Szostak et al, 1996).…”

Section: Current Strategies and Development Of Burkholderia Vaccinesmentioning

confidence: 99%

Burkholderia vaccines: are we moving forward?

Choh¹,

Ong²,

Vellasamy³

et al. 2013

Front. Cell. Inf. Microbio.

View full text Add to dashboard Cite

The genus Burkholderia consists of diverse species which includes both “friends” and “foes.” Some of the “friendly” Burkholderia spp. are extensively used in the biotechnological and agricultural industry for bioremediation and biocontrol. However, several members of the genus including B. pseudomallei, B. mallei, and B. cepacia, are known to cause fatal disease in both humans and animals. B. pseudomallei and B. mallei are the causative agents of melioidosis and glanders, respectively, while B. cepacia infection is lethal to cystic fibrosis (CF) patients. Due to the high rate of infectivity and intrinsic resistance to many commonly used antibiotics, together with high mortality rate, B. mallei and B. pseudomallei are considered to be potential biological warfare agents. Treatments of the infections caused by these bacteria are often unsuccessful with frequent relapse of the infection. Thus, we are at a crucial stage of the need for Burkholderia vaccines. Although the search for a prophylactic therapy candidate continues, to date development of vaccines has not advanced beyond research to human clinical trials. In this article, we review the current research on development of safe vaccines with high efficacy against B. pseudomallei, B. mallei, and B. cepacia. It can be concluded that further research will enable elucidation of the potential benefits and risks of Burkholderia vaccines.

show abstract

Section: Current Strategies and Development Of Burkholderia Vaccinesmentioning

confidence: 99%

Burkholderia vaccines: are we moving forward?

Choh¹,

Ong²,

Vellasamy³

et al. 2013

Front. Cell. Inf. Microbio.

View full text Add to dashboard Cite

show abstract

“…Two or more recombinant proteins can also be genetically fused to create a multivalent vaccine [63], which may overcome some of the logistical and manufacturing problems that would be associated with a vaccine composed of multiple antigens. Studies of other novel antigens, including Omp18, TonB, superoxide dismutase, and protein‐conjugated LPS, are preliminary [64–67].…”

Section: Vaccine Developmentmentioning

confidence: 99%

Inflammation, Immunity, and Vaccine Development for Helicobacter pylori

Müller

Solnick

2011

Helicobacter

View full text Add to dashboard Cite

The immune response to Helicobacter pylori entails both innate effectors and a complex mix of Th1, Th17, and Treg adaptive immune responses. The clinical outcome of infection may well depend to a large degree on the relative balance of these responses. Vaccination with a wide range of antigens, adjuvants, and delivery routes can produce statistically significant reductions in H. pylori colonization levels in mice, though rarely sterilizing immunity. Whether similar reductions in bacterial load can be achieved in humans, and whether they would be clinically significant, is still unclear. However, progress in understanding the role of Th1, Th17, and most recently Treg cells in protection against H. pylori infection provides reason for optimism.

show abstract

“…Thus, these cell surface-expressed proteins are logical candidates for vaccine development. Talebkhan and colleagues (27) H. pylori is known to cause chronic active gastritis, which is typically characterized by considerable infiltration of inflammatory cells into the gastric mucosa. Neutrophils are thought to mediate gastritis activity and play a critical role in H. pyloriinduced mucosal injuries (8,33).…”

Section: Discussionmentioning

confidence: 99%

Oral Immunization with Recombinant Mycobacterium smegmatis Expressing the Outer Membrane Protein 26-Kilodalton Antigen Confers Prophylactic Protection against Helicobacter pylori Infection

Lin

Zeng

Pi-long

et al. 2011

Clin Vaccine Immunol

View full text Add to dashboard Cite

Helicobacter pylori infection is prevalent worldwide and results in chronic gastritis, which may lead to gastric mucosa-associated lymphoid tissue lymphoma and gastric cancer. We have previously reported that oral immunization with recombinant Mycobacterium smegmatis expressing the H. pylori outer membrane protein 26-kilodalton (Omp26) antigen affords therapeutic protection against H. pylori infection in mice. In the present study, we investigated the prophylactic effects of this vaccine candidate on H. pylori challenge in mice. We found that oral immunization with recombinant Mycobacterium Omp26 significantly reduced H. pylori colonization in the stomach compared to inoculation with wild-type M. smegmatis in control mice. Six of the recombinant Mycobacterium-immunized mice (60%) were completely protected from H. pylori infection. The severity of H. pylori-associated chronic gastritis assessed histologically was significantly milder in mice vaccinated with recombinant Mycobacterium than in control animals. Mice immunized with recombinant Mycobacterium showed enhanced antigen-specific lymphocyte proliferation and antibody responses. Moreover, immunization with recombinant Mycobacterium resulted in an increased expression of interleukin-2 and gamma interferon in the stomach and spleen, as determined by reverse transcription-PCR analysis. Our results collectively suggest that vaccination with recombinant Mycobacterium Omp26 confers prophylactic protection against H. pylori infection. The inhibition of H. pylori colonization is associated with the induction of antigen-specific humoral and cell-mediated immune responses.

show abstract

Helicobacter pylori bacterial ghost containing recombinant Omp18 as a putative vaccine

Cited by 26 publications

References 30 publications

Burkholderia vaccines: are we moving forward?

Burkholderia vaccines: are we moving forward?

Inflammation, Immunity, and Vaccine Development for Helicobacter pylori

Oral Immunization with Recombinant Mycobacterium smegmatis Expressing the Outer Membrane Protein 26-Kilodalton Antigen Confers Prophylactic Protection against Helicobacter pylori Infection

Contact Info

Product

Resources

About